Press Releases

Acticor Biotech raises €15.3M in a Series B financing

Paris, October 17, 2018 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism, today announced that it has completed a €15.3 million Series B round of financing from European and Asian investors. This new funding will enable the company to finance its first […]
Read more

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

Paris, July 31, 2018 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism, announces the signature of an Asset Transfer and Licensing agreement covering a development and commercialisation collaboration agreement with CMS Medical Limited as well as an investment agreement with CMS Medical […]
Read more

ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE

Paris, April 25th, 2018 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism, has discussed with the European Medicines Agency (EMA) the development of its drug candidate, ACT017. This meeting follows the completion of the first-in-human study in January 2018 which provided preliminary […]
Read more

ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS

Paris, February 5th, 2018 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and other thrombosis disorders like pulmonary embolism, announced today the completion of its phase I clinical trial in healthy volunteers with its drug candidate, ACT017. ACT017 is a humanized monoclonal antibody fragment (Fab) […]
Read more

Acticor Biotech announces the closing of a €1,7 million equity financing led by Primer Capital

Paris, January 4th, 2018 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and other thrombosis disorders like pulmonary embolism, announces today the closing of an equity financing led by Primer Capital. The financing round includes investments in equity from Primer Capital and historical shareholders Anaxago, […]
Read more
Page 1 of 3123